Citations

Clear

9383 citation(s) found for "Thomas, PS".

Etiology of White Matter Hyperintensities in Autosomal Dominant and Sporadic Alzheimer Disease
Shirzadi, Zahra , Schultz, Stephanie A. , Yau, Wai‐Ying Wendy , Fitzpatrick, Colleen , Levin, Raina, Kantarci, Kejal , Preboske, Gregory M., Jack, Clifford R. , Farlow, Martin R. , Hassenstab, Jason , Morris, John C. , Xiong, Chengjie , Levey, Allan I. , Gordon, Brian A. , Salloway, Stephen , Perrin, Richard J. , Xiong, Chengjie , Fox, Nick C. , Goate, Alison , Day, Gregory S. , Chui, Helena C., Berman, Sarah , Mori, Hiroshi , Ruthirakuhan, Myuri , Wu, Che‐Yuan , Sohrabi, Hamid R. , Martins, Ralph N. , Johnson, Keith A. , Greenberg, Steven M. , Chhatwal, Jasmeer P. , Initiative, Dominantly Inherited Alzheimer Network and the Alzheimer’s Disease Neuroimaging, Weiner, Michael W. , Aisen, Paul, Petersen, Ronald , Jack, Clifford R., Jagust, William J. , Trojanowki, John Q., Morris, John C., Shaw, Leslie M. , Khachaturian, Zaven S., Carrillo, Maria, Potter, William Z., Bernard, Marie , Jackson, Jonathan , Masliah, Eliezer , Masterman, Donna, Okonkwo, Ozioma C. , Ryan, Laurie, Silverberg, Nina, Fleisher, Adam , Sacrey, Diana Truran, Fockler, Juliet , Conti, Cat, Jin, Chengshi , Nosheny, Rachel L. , Ashford, Miriam T. , Flenniken, Derek , Kormos, Adrienne, Montine, Tom, Raman, Rema , Jiménez, Gustavo , Gessert, Devon, Salazar, Jennifer, Zimmerman, Caileigh, Cabrera, Yuliana, Walter, Sarah , Miller, Garrett, Coker, Godfrey, Clanton, Taylor, Hergesheimer, Lindsey, Adegoke, Olusegun, Mahboubi, Payam, Moore, Shelley, Pizzola, Jeremy, Shaffer, Elizabeth , Sloan, Brittany, Forghanian-Arani, Arvin, Borowski, Bret, Ward, Chad, Gunter, Jeff, Jahanshad, Neda , DeCarli, Charles, Knaack, Alexander , Chen, Stephanie Rossi, Choe, Mark, Crawford, Karen , Reiman, Eric M. , Mathis, Chet, Landau, Susan, Cairns, Nigel J., Householder, Erin, Franklin, Erin , Bernhardt, Haley, Taylor‐Reinwald, Lisa, Korecka, Magdalena , Figurski, Michael, Neu, Scott, Apostolova, Liana G. , Foroud, Tatiana M., Faber, Kelley, Wilmes, Kristi, Thal, Leon J., Lind, Betty, Crissey, Rachel, Carter, Raina, Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Becerra, Mauricio, Teodoro, Liberty, Dagerman, Karen, Spann, Bryan M., Brewer, James B., Vanderswag, Helen, Ziolkowski, Jaimie, Heidebrink, Judith L. , Zbizek-Nulph, Lisa, Mason, Sara S., Albers, Colleen S., Johnson, Kris , Villaneuva-Meyer, Javier, Pavlik, Valory , Pacini, Nathaniel, Lamb, Ashley, Kass, Joseph S. , Doody, Rachelle S., Shibley, Victoria, Chowdhury, Munir , Rountree, Susan, Dang, Mimi, Mintz, Akiva , Winkfield, David, Carroll, Maria , Stobbs-Cucchi, Georgia , Oliver, Angela , Creech, Mary L., Mintun, Mark A., Schneider, Stacy, Geldmacher, David , Love, Marissa Natelson , Griffith, Randall, Clark, David, Brockington, John, Marson, Daniel , Grossman, Hillel, Goldstein, Martin , Mitsis, Effie, Samuels, Patricia, Duara, Ranjan , Greig‐Custo, Maria T., Rodriguez, Rosemarie, Albert, Marilyn, Onyike, Chiadi, Farrington, Leonie, Rudow, Scott, Brichko, Rottislav, Kielb, Stephanie , Smith, Amanda , Raj, Balebail Ashok, Fargher, Kristin, Shulman, Melanie , Faustin, Arline , Rao, Julia, Castro, Karen M. , Ulysse, Anaztasia, Chen, Shannon, Sheikh, Mohammed O., Singleton-Garvin, Jamika, Doraiswamy, P. Murali , Petrella, Jeffrey R. , James, Olga, Borges‐Neto, Salvador , Karlawish, Jason , Vaishnavi, Sanjeev , Clark, Christopher M. , Arnold, Steven E. , Smith, Charles D. , Khouli, Riham El , Raslau, Flavius D., Oakley, MaryAnn, Simpson, Donna M., Martin, Kim, Kowalski, Nancy, Keltz, Melanie, Goldstein, Bonnie S., Makino, Kelly M., Ismail, M. Saleem , Brand, Connie, Thai, Gaby , Pierce, Aimee, Witbracht, Megan , Mathews, Dana, Quiceno, Mary , Hajjar, Ihab , Cellar, Janet S., Swerdlow, Russell H. , Kremen, Sarah , Tingus, Kathleen, Lu, Po H. , Bartzokis, George, Woo, Ellen, Graff‐Radford, Neill R. , Parfitt, Francine, Poki-Walker, Kim, Hake, Ann Marie , Matthews, Brandy R., Herring, Scott, Dyck, Christopher H. van , Mecca, Adam P. , Good, Susan P., MacAvoy, Martha G., Carson, Richard E. , Varma, Pradeep, Chertkow, Howard , Vaitekunis, Susan, Hosein, Chris, Mudge, Benita, Assaly, Michele, Rachinsky, Irina, Kertesz, Andrew, Drost, Dick, Rogers, John, Grant, Ian , Muse, Brittanie, Rogalskı, Emily , Robson, Jordan, Mesulam, M.‐Marsel, Kerwin, Diana , Wu, Chuang‐Kuo, Johnson, Nancy E., Lipowski, Kristine, Weıntraub, Sandra , Bonakdarpour, Borna , Hernando, Raymundo, Sarrael, Antero, Rosen, Howard J., Johnson, Kathleen, Reynolds, Brigid, Poe, Jessica, Sperling, Reisa A., Marshall, Gad A. , Yesavage, Jerome A. , Taylor, Joy L. , Chao, Steven, Coleman, Jaila, White, Jessica D. , Lane, Barton , Rosen, Allyson , Tinklenberg, Jared, Belden, Christine M. , Clark, Kelly, Zamrini, Edward , Sabbagh, Marwan, Kowall, Neil W. , Budson, Andrew E. , Ntekim, Oyonumo, Wolday, Saba, Khan, Javed , Nwulia, Evaristus , Nadarajah, Sheeba , Lerner, Alan J. , Ogrocki, Paula, Tatsuoka, Curtis , Fatica, Parianne, Olichney, John , Bates, Vernice, Capote, Horacio, Rainka, Michelle, Borrie, Michael, Lee, T‐Y, Asthana, Sanjay , Carlsson, Cynthia M., Perrin, Allison, Burke, Anna , Kataki, Maria , Hart, David , Zimmerman, Earl A. , Celmins, Dzintra, Smith, Karen Ekstam, Shim, Hyungsub , Nam, Ki Won , Schtulz, Susan K., Williamson, Jeff D. , Craft, Suzanne , Cleveland, Jo, Ott, Brian R. , Drake, Jonathan, Tremont, Geoffrey , Daiello, Lori A. , Ritter, Aaron, Bernick, Charles , Munic, Donna, O’Connell, Abigail, Mintzer, Jacobo , Wiliams, Arthur, Masdeu, Joseph C. , Shi, Jiong , Garcia, Angelica, Newhouse, Paul , Salloway, Steven, Malloy, Paul, Correia, Stephen , Kittur, Smita, Blank, Karen, Anderson, Karen, Flashman, Laura A. , Seltzer, Marc, Hynes, Mary L. , Santulli, Robert B. , Relkin, Norman , Chiang, Gloria, Lee, Athena, Lin, Michael, Ravdin, Lisa , Sood, Ajay, Blanchard, Kimberly S., Fleischman, Debra , Varon, Daniel, Greig, Maria T., Martin, Kimberly S., Reist, Christopher , Sadowsky, Carl, Villena, Teresa, Rosen, Howard, Peskind, Elaine R. , Li, Gail, Vöglein, Jonathan , Méndez, Patricio Chrem, Ikonomović, Snežana, Nadkarni, Neelesh K. , Ramírez, Laura, Leon, Yudy Milena, Ramos, Cláudia , Alzate, Diana, Baena, Ana , Londono, Natalia, Laske, Christoph , Kuder-Buletta, Elke, Gräber‐Sultan, Susanne, Preische, Oliver, Hofmann, Anna, Ishii, Kenji , Senda, Michio , Riddle, Meghan C., Menard, William, Bodge, Courtney, Surti, Mustafa, Sanchez-Gonzalez, VJ, Orozco-Barajas, Maribel, Esposito, Bianca, Fernanadez, Victoria, Jerome, Gina, Herries, Elizabeth, Seyfried, Nicholas T. , Bechara, Jacob , Chen, Allison , Hantler, Nancy, Hornbeck, Russ C. , Jarman, Steve, Keefe, Sarah , Koudelis, Deborah, Massoumzadeh, Parinaz , Nicklaus, Joyce , Pulizos, Christine, Mishall, Sheetal, Sabaredzovic, Edita, Deng, Emily , Candela, Madison, Smith, Hunter , Scott, Jalen , Gremminger, Emily, Ma, Yinjiao , Bui, Ryan , Lu, Ruijin , Daniels, Alisha , Courtney, Laura, Supnet, Charlene , Xu, Jinbin , Ringman, John M. , Barthélemy, Nicolas R. , Jack, Clifford R , Gordon, Brian A , Kantarci, Kejal , Day, Gregory S , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Supnet-Bell, Charlene , Berman, Sarah , Levey, Allan I , Kremen, Sarah , Joseph‐Mathurin, Nelly , Jucker, Mathias , Xiong, Chengjie , Karch, Celeste M. , Schofield, Peter R. , McDade, Eric , Cruchaga, Carlos , Allegri, Ricardo , Koeppe, Robert A. , Chui, Helena C. , Sánchez‐Valle, Raquel , Lee, Jae‐Hong , Rosa-Neto, Pedro , Swardfager, Walter , Benzinger, Tammie L.S. , Bateman, Randall J. , Sperling, Reisa Anne , Schultz, Aaron P. , Initiative, Dominantly Inherited Alzheimer Network and the Alzheimer’s Disease Neuroimaging, Jack, Clifford R., Toga, Arthur W. , Beckett, Laurel , Green, Robert C. , Saykin, Andrew J. , Morris, John C., Barnes, Lisa L. , González, Hector, Ho, Carole , Hsiao, John , Veitch, Dallas P. , Neuhaus, John M , Rafii, Michael S. , Donohue, Michael , Smith, Stephanie R. , Harvey, Danielle , Arani, Arvin , Schwarz, Christopher G. , Jones, David T. , Senjem, Matthew L. , Vemuri, Prashanthi , Reid, Robert I. , Malone, Ian B. , Thompson, Paul M. , Thomopoulos, Sophia I. , Nir, Talia M. , Fletcher, Evan M. , Tosun, Duygu , Yushkevich, Paul A. , Das, Sandhitsu R. , Chen, Kewei , Mathis, Chet, Nho, Kwangsik T. , Risacher, Shannon L. , Shen, Li , Nudelman, Kelly , Silbert, Lisa C. , Kaye, Jeffrey , Carter, Raina, Quinn, Joseph F. , Lord, Joanne L. , Knopman, David S. , Stern, Yaakov , Honig, Lawrence S. , Ances, Beau M. , Goldstein, Martin A., Greenberg, Jonathan, Shah, Raj C. , Lamar, Melissa , Duara, Ranjan , Sadowski, Martin , Wısnıewskı, Thomas , Wong, Terence Z. , Wolk, David A. , Jicha, Gregory A. , López, Oscar L. , Porsteinsson, Anton P. , Yanez, Beatriz, Sosa, Elizabeth M. , Kelley, Brendan , Nguyen, Trung Dung , Womack, Kyle , Lah, James J. , Burns, Jeffrey M. , Brooks, William Miles , Silverman, Daniel H.S. , Teng, Edmond , Brosch, Jared R. , Black, Sandra E. , Stefanovic, Bojana , Heyn, Chris , Hsiung, Ging‐Yuek Robin , Kim, Ellen , Sossi, Vesna , Feldman, Howard , Finger, Elizabeth C. , Pasternak, Stephen , Miller, Bruce L. , Perry, David C. , Turner, Raymond Scott , MCCann, Kelly, Sperling, Reisa A., Atri, Alireza , Killiany, Ronald , Stern, Robert A. , Mez, Jesse , Obisesan, Thomas O. , Maillard, Pauline , Carmichael, Owen , Bartha, Robert , Johnson, Sterling C. , Carlsson, Cynthia M. , Scharre, Douglas W. , Tarawneh, Rawan M. , Miller, Del D. , Ponto, Laura L. Boles , Koleva, Hristina , Yang, Mia , Sink, Kaycee M. , Masdeu, Joseph C , Potkin, Steven G. , Salloway, Steve , Pearlson, Godfrey D. , Sood, Ajay, Arfanakis, Konstantinos , Varón, Daniel , Martínez, Walter Fabián , Petrie, Eric C. , Noble, James M. , Surace, Ezequiel , Lopera, Francisco Javier , Aguillon, David , Londono, Natalia, Moreno, Sonia, Ikeuchi, Takeshi , Kasuga, Kensaku , Niimi, Yoshiki , Cash, David M. , Roh, Jee Hoon , Takada, Leonel Tadao , Renton, Alan , Marsh, Jacob A. , Llibre‐Guerra, Jorge J. , Johnson, Erik C. B. , Brooks, William S. , Chen, Charles , Flores, Shaney , McCullough, Austin , McKay, Nicole S. , Wáng, Qīng , Candela, Madison, Hobbs, Diana A. , Wang, Peter , Xu, Xiong, Li, Yan , Sosa, Ana Luisa , Smith, Jennifer A.

Mayo Clinic

JAMA Neurology | October 16, 2023 | Volume: 80 | Issue: 12 | Pages: 1353

10.1001/jamaneurol.2023.3618 | PMID 37843849 Get It

ImportanceIncreased white matter hyperintensity (WMH) volume is a common magnetic resonance imaging (MRI) finding in both autosomal dominant Alzheimer disease (ADAD) and late-onset Alzheimer disease (LOAD), but it remains unclear whether increased WMH along the AD continuum is reflective of AD-intrinsic processes or secondary to elevated systemic vascular risk factors.ObjectiveTo estimate the associations of neurodegeneration and parenchymal and vessel amyloidosis with WMH accumulation and investigate whether systemic vascular risk is associated with WMH beyond these AD-intrinsic processes.Design, Setting, and ParticipantsThis cohort study used data from 3 longitudinal cohort studies conducted in tertiary and community-based medical centers—the Dominantly Inherited Alzheimer Network (DIAN; February 2010 to March 2020), the Alzheimer’s Disease Neuroimaging Initiative (ADNI; July 2007 to September 2021), and the Harvard Aging Brain Study (HABS; September 2010 to December 2019).Main Outcome and MeasuresThe main outcomes were the independent associations of neurodegeneration (decreases in gray matter volume), parenchymal amyloidosis (assessed by amyloid positron emission tomography), and vessel amyloidosis (evidenced by cerebral microbleeds [CMBs]) with cross-sectional and longitudinal WMH.ResultsData from 3960 MRI sessions among 1141 participants were included: 252 pathogenic variant carriers from DIAN (mean [SD] age, 38.4 [11.2] years; 137 [54%] female), 571 older adults from ADNI (mean [SD] age, 72.8 [7.3] years; 274 [48%] female), and 318 older adults from HABS (mean [SD] age, 72.4 [7.6] years; 194 [61%] female). Longitudinal increases in WMH volume were greater in individuals with CMBs compared with those without (DIAN: t = 3.2 [P = .001]; ADNI: t = 2.7 [P = .008]), associated with longitudinal decreases in gray matter volume (DIAN: t = −3.1 [P = .002]; ADNI: t = −5.6 [P < .001]; HABS: t = −2.2 [P = .03]), greater in older individuals (DIAN: t = 6.8 [P < .001]; ADNI: t = 9.1 [P < .001]; HABS: t = 5.4 [P < .001]), and not associated with systemic vascular risk (DIAN: t = 0.7 [P = .40]; ADNI: t = 0.6 [P = .50]; HABS: t = 1.8 [P = .06]) in individuals with ADAD and LOAD after accounting for age, gray matter volume, CMB presence, and amyloid burden. In older adults without CMBs at baseline, greater WMH volume was associated with CMB development during longitudinal follow-up (Cox proportional hazards regression model hazard ratio, 2.63; 95% CI, 1.72-4.03; P < .001).Conclusions and RelevanceThe findings suggest that increased WMH volume in AD is associated with neurodegeneration and parenchymal and vessel amyloidosis but not with elevated systemic vascular risk. Additionally, increased WMH volume may represent an early sign of vessel amyloidosis preceding the emergence of CMBs.
The Future Ain’t What It Used to Be…Out With the Old…In With the Better: Antibacterial Resistance Leadership Group Innovations
Patel, Robin , Hamasaki, Toshimitsu , Howard‐Anderson, Jessica , Kinamon, Tori, King, H. A. , Cross, H. R. , Chambers, Henry F. , Fowler, Vance G. , Boucher, Helen W., Group, for the Antibacterial Resistance Leadership, Schooley, Robert T. , Banerjee, Ritu , Souli, Maria , Sund, Zoë, Evans, Beth , Booth, Grant, Estes, Leslie, Greenwood‐Quaintance, Kerryl E. , Parmar, Krupa , Schwager, Nyssa, Wickward, Cathy, Geres, Holly, Dai, Weixiao , He, Yijie, Doernberg, Sarah B. , Satlin, Michael J. , Rouphael, Nadine , Baum, Keri, Raza, Praneeta , Komarow, Lauren , Hopkins, D. E., Zhang, Shanshan , Patel, Robin , Evans, Scott R , Evans, Scott , King, Heather A, Collyar, Deborah , Cross, Heather R, Fowler, Vance G. , Group, for the Antibacterial Resistance Leadership, Tamma, Pranita D. , Evans, Beth, Cunningham, Scott A. , Tillekeratne, L. Gayani , Dodd, Andrew, Hopkins, Deborah, Li, Yixuan , Tsalik, Ephraim L. , Holland, Thomas L

Mayo Clinic

Clinical Infectious Diseases | October 16, 2023 | Volume: 77 | Issue: Supplement_4 | Pages: S321-S330

10.1093/cid/ciad538 | PMID 37843122 Get It

Abstract Clinical research networks conduct important studies that would not otherwise be performed by other entities. In the case of the Antibacterial Resistance Leadership Group (ARLG), such studies include diagnostic studies using master protocols, controlled phage intervention trials, and studies that evaluate treatment strategies or dynamic interventions, such as sequences of empiric and definitive therapies. However, the value of a clinical research network lies not only in the results from these important studies but in the creation of new approaches derived from collaborative thinking, carefully examining and defining the most important research questions for clinical practice, recognizing and addressing common but suboptimal approaches, and anticipating that the standard approaches of today may be insufficient for tomorrow. This results in the development and implementation of new methodologies and tools for the design, conduct, analyses, and reporting of research studies. These new methodologies directly impact the studies conducted within the network and have a broad and long-lasting impact on the field, enhancing the scientific value and efficiency of generations of research studies. This article describes innovations from the ARLG in diagnostic studies, observational studies, and clinical trials evaluating interventions for the prevention and treatment of antibiotic-resistant bacterial infections.
The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions
Chambers, Henry F. , Cross, H. R. , Souli, Maria , Patel, Robin , Fowler, Vance G. , Group, for the Antibacterial Resistance Leadership, Deckard, Nancie , Schuler, Carl, Bunn, Ivra, Zaharoff, Smitha, Sharma, Shrabani, Wickward, Cathy, Waller, Jason, Wilson, Holly, Baum, Keri, Komarow, Lauren , Evans, Beth , Hopkins, D. E., Ge, Lizhao , Giri, Abhigya, Dai, Weixiao , Diao, Guoqing , Fidler, Tamara, Shao, Wanying, Schwager, Nyssa, Mau, Donald, Satlin, Michael J. , Schooley, Robert T. , Sund, Zoë, Booth, Grant, Estes, Leslie, Greenwood‐Quaintance, Kerryl E. , Parmar, Krupa , Doernberg, Sarah B. , Raza, Praneeta , Zeng, Lijuan , Banerjee, Ritu , Abbenante, Erin, Mocka, Elizabeth, King, H. A. , Kinamon, Tori, Boucher, Helen W., Geres, Holly, He, Yijie, Mehigan, Maureen, Ghazaryan, Varduhi , Raterman, Erica L., Samuel, Tamika, Lee, Marina S. , Fowler, Vance G. , Patel, Robin , Evans, Scott R , Cross, Heather R, Evans, Scott , Group, for the Antibacterial Resistance Leadership, Lodise, Thomas P. , Schuler, Carl, Holland, Thomas L , Turner, Nicholas , Wilson, Holly, van Duin, David , Wang, Minggui, Evans, Beth, Hopkins, Deborah, Bonomo, Robert A. , Li, Yixuan , Tamma, Pranita D. , Hamasaki, Toshimitsu , Cunningham, Scott A. , Dodd, Andrew, Tsalik, Ephraim L. , Tillekeratne, L. Gayani , King, Heather, Kinamon, Tori, Howard‐Anderson, Jessica , Nayak, Seema , Samuel, Tamika

Mayo Clinic

Clinical Infectious Diseases | October 16, 2023 | Volume: 77 | Issue: Supplement_4 | Pages: S279-S287

10.1093/cid/ciad475 | PMID 37843121 Get It

AbstractIn this overview, we describe important contributions from the Antibacterial Resistance Leadership Group (ARLG) to patient care, clinical trials design, and mentorship while outlining future priorities. The ARLG research agenda is focused on 3 key areas: gram-positive infections, gram-negative infections, and diagnostics. The ARLG has developed an innovative approach to clinical trials design, the desirability of outcome ranking (DOOR), which uses an ordinal measure of global outcome to assess both benefits and harms. DOOR was initially applied to observational studies to determine optimal dosing of vancomycin for methicillin-resistant Staphylcococcus aureus bacteremia and the efficacy of ceftazidime-avibactam versus colistin for the treatment of carbapenem-resistant Enterobacterales infection. DOOR is being successfully applied to the analysis of interventional trials and, in collaboration with the US Food and Drug Administration (FDA), for use in registrational trials. In the area of diagnostics, the ARLG developed Master Protocol for Evaluating Multiple Infection Diagnostics (MASTERMIND), an innovative design that allows simultaneous testing of multiple diagnostic platforms in a single study. This approach will be used to compare molecular assays for the identification of fluoroquinolone-resistant Neisseria gonorrhoeae (MASTER GC) and to compare rapid diagnostic tests for bloodstream infections. The ARLG has initiated a first-in-kind randomized, double-blind, placebo-controlled trial in participants with cystic fibrosis who are chronically colonized with Pseudomonas aeruginosa to assess the pharmacokinetics and antimicrobial activity of bacteriophage therapy. Finally, an engaged and highly trained workforce is critical for continued and future success against antimicrobial drug resistance. Thus, the ARLG has developed a robust mentoring program targeted to each stage of research training to attract and retain investigators in the field of antimicrobial resistance research.
Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group
Satlin, Michael J. , Tyne, Daria Van , Rouphael, Nadine , Fowler, Vance G. , Hamasaki, Toshimitsu , Patel, Robin , Komarow, Lauren , Baum, Keri, Souli, Maria , Schwager, Nyssa, Doi, Yohei , Group, for the Antibacterial Resistance Leadership, Schooley, Robert T., Evans, Beth , Hopkins, D. E., Cathcart, F, Mocka, Elizabeth, Schuler, Carl, Sund, Zoë, Zaharoff, Smitha, Wickward, Cathy, Estes, Leslie, Mau, Donald, Booth, Grant, Abbenante, Erin, Bhojani, Minal, Zahir, Hirra, Ge, Lizhao , Giri, Abhigya, Dai, Weixiao , Diao, Guoqing , Fidler, Tamara, Shao, Wanying, Li, Yixuan , Zeng, Lijuan , Zhang, Shanshan , Greenwood‐Quaintance, Kerryl E. , Malan, Suzannah Schmidt, Parmar, Krupa , Ghazaryan, Varduhi , Raterman, Erica L., Samuel, Tamika, Lee, Marina S. , Doi, Yohei , Patel, Robin , Van Tyne, Daria , Evans, Scott R , van Duin, David , Tamma, Pranita D. , Lodise, Thomas P. , Rodvold, Keith A. , Evans, Scott , Fowler, Vance G. , Bonomo, Robert A. , Group, for the Antibacterial Resistance Leadership, Wang, Minggui, Wenzler, Eric , Evans, Beth, Hopkins, Deborah, Cathcart, Felecia, Schuler, Carl, Cunningham, Scott A. , Samuel, Tamika, Nayak, Seema

Mayo Clinic

Clinical Infectious Diseases | October 16, 2023 | Volume: 77 | Issue: Supplement_4 | Pages: S305-S313

10.1093/cid/ciad547 | PMID 37843118 Get It

Abstract Addressing the treatment and prevention of antibacterial-resistant gram-negative bacterial infections is a priority area of the Antibacterial Resistance Leadership Group (ARLG). The ARLG has conducted a series of observational studies to define the clinical and molecular global epidemiology of carbapenem-resistant and ceftriaxone-resistant Enterobacterales, carbapenem-resistant Pseudomonas aeruginosa, and carbapenem-resistant Acinetobacter baumannii, with the goal of optimizing the design and execution of interventional studies. One ongoing ARLG study aims to better understand the impact of fluoroquinolone-resistant gram-negative gut bacteria in neutropenic patients, which threatens to undermine the effectiveness of fluoroquinolone prophylaxis in these vulnerable patients. The ARLG has conducted pharmacokinetic studies to inform the optimal dosing of antibiotics that are important in the treatment of drug-resistant gram-negative bacteria, including oral fosfomycin, intravenous minocycline, and a combination of intravenous ceftazidime-avibactam and aztreonam. In addition, randomized clinical trials have assessed the safety and efficacy of step-down oral fosfomycin for complicated urinary tract infections and single-dose intravenous phage therapy for adult patients with cystic fibrosis who are chronically colonized with P. aeruginosa in their respiratory tract. Thus, the focus of investigation in the ARLG has evolved from improving understanding of drug-resistant gram-negative bacterial infections to positively affecting clinical care for affected patients through a combination of interventional pharmacokinetic and clinical studies, a focus that will be maintained moving forward.
Microfibrillar-associated protein 4 as a potential marker of acute relapse in inflammatory demyelinating diseases of the central nervous system: Pathological and clinical aspects
Samadzadeh, Sara , Olesen, Mads Nikolaj , Wirenfeldt, Martin , Möller, Sören , Misu, Tatsuro , Soelberg, Kerstin , Frederiksen, Jette Lautrup , Ruprecht, Klemens , Andersen, Thomas Levin , Marignier, Romain , Lillevang, Søren Thue , Pittock, Sean J, Kim, Ho Jin , Bennett, Jeffrey L. , Paul, Friedemann , Sørensen, Grith Lykke , Weinshenker, Brian G. , Pittock, Sean J. , Pittock, S J , Marignier, Romain , Flanagan, E P , Pittock, Sean J , Kim, Ho Jin , Bennett, Jeffrey L , Weinshenker, Brian G , Paul, Friedemann , Heegaard, Steffen , Mariotto, Sara , Fujihara, Kazuo , Flanagan, Eoin P. , Lassmann, Hans , Asgari, Nasrin

Mayo Clinic

Multiple Sclerosis Journal | October 13, 2023 | Volume: 29 | Issue: 14 | Pages: 1721-1735

10.1177/13524585231200720 | PMID 37830484 Get It

Background: Microfibrillar-associated protein 4 (MFAP4) is an extracellular matrix protein not previously described in the human central nervous system (CNS). Objectives: We determined MFAP4 CNS expression and measured cerebrospinal fluid (CSF) and serum levels. Methods: Tissue was sampled at autopsy from patients with acute multiple sclerosis (MS) ( n = 3), progressive MS ( n = 3), neuromyelitis optica spectrum disorder (NMOSD) ( n = 2), and controls ( n = 9), including 6 healthy controls (HC). MFAP4 levels were measured in 152 patients: 49 MS, 62 NMOSD, 22 myelin oligodendrocyte glycoprotein-associated disease (MOGAD), and 19 isolated optic neuritis (ION). Results: MFAP4 localized to meninges and vascular/perivascular spaces, intense in the optic nerve. At sites of active inflammation, MFAP4 reactivity was reduced in NMOSD and acute MS and less in progressive MS. CSF MFAP4 levels were reduced during relapse and at the onset of diseases (mean U/mL: MS 14.3, MOGAD 9.7, and ION 14.6 relative to HC 17.9. ( p = 0.013, p = 0.000, and p = 0.019, respectively). Patients with acute ON ( n = 68) had reduced CSF MFAP4 (mean U/mL: 14.5, p = 0.006). CSF MFAP4 levels correlated negatively with relapse severity (rho = −0.41, p = 0.017). Conclusion: MFAP4 immunoreactivity was reduced at sites of active inflammation. CSF levels of MFAP4 were reduced following relapse and may reflect disease activity.
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology
Schaeffer, Edward M. , Srinivas, Sandy, An, Yi , Barocas, Daniel A. , Bitting, Rhonda L. , Bryce, Alan H. , Chapin, Brian F. , D’Amico, Anthony V. , Desai, Neil , Dorff, Tanya B. , Eastham, James A., Farrington, Thomas A., Gao, Xin , Gupta, Shilpa , Guzzo, Thomas, Kuettel, Michael, McKay, Rana R. , Morgan, Todd M. , Pow‐Sang, Julio M. , Reiter, Robert E. , Roach, Mack , Rosenfeld, Stan, Shabsigh, Ahmad , Valicenti, Richard K., Wong, J.K. , Shead, Dorothy A. , Snedeker, Jenna, Freedman-Cass, Deborah A., Bryce, Alan, Bryce, Alan H , Morgan, Todd M , Robin, Tyler P. , Adra, Nabil , Cheng, Heather H. , Ippolito, Joseph E. , Lang, Joshua M. , Lotan, Tamara Levin , Netto, George J. , Spratt, Daniel E. , Teply, Benjamin A. , Tward, Jonathan D.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | October 12, 2023 | Volume: 21 | Issue: 10 | Pages: 1067-1096

10.6004/jnccn.2023.0050 | PMID 37856213 Get It

The NCCN Guidelines for Prostate Cancer provide a framework on which to base decisions regarding the workup of patients with prostate cancer, risk stratification and management of localized disease, post-treatment monitoring, and treatment of recurrence and advanced disease. The Guidelines sections included in this article focus on the management of metastatic castration-sensitive disease, nonmetastatic castration-resistant prostate cancer (CRPC), and metastatic CRPC (mCRPC). Androgen deprivation therapy (ADT) with treatment intensification is strongly recommended for patients with metastatic castration-sensitive prostate cancer. For patients with nonmetastatic CRPC, ADT is continued with or without the addition of certain secondary hormone therapies depending on prostate-specific antigen doubling time. In the mCRPC setting, ADT is continued with the sequential addition of certain secondary hormone therapies, chemotherapies, immunotherapies, radiopharmaceuticals, and/or targeted therapies. The NCCN Prostate Cancer Panel emphasizes a shared decision-making approach in all disease settings based on patient preferences, prior treatment exposures, the presence or absence of visceral disease, symptoms, and potential side effects.
Contemporary diagnostic visual and automated polysomnographic REM sleep without atonia thresholds in isolated REM sleep behavior disorder
Feemster, John, Bibi, Noor, Gossard, Thomas , Jagielski, Jack T. , Strainis, Emma, Timm, Paul, Silber, Michael H. , McCarter, Stuart J. , LeClair-Visonneau, Laurene , Feemster, John C, Strainis, Emma P, Carvalho, Diego Z. , Timm, Paul C, St Louis, Erik K, Gossard, Thomas R , Jagielski, Jack , McCarter, Stuart J , Leclair‐Visonneau, Laurène , Bliwise, Donald L. , Boeve, Bradley F. , Louis, Erik K. St.

Mayo Clinic

Journal of Clinical Sleep Medicine | October 12, 2023 | Volume: 20 | Issue: 2 | Pages: 279-291

10.5664/jcsm.10862 | PMID 37823585 Get It

ZNF432 stimulates PARylation and inhibits DNA resection to balance PARPi sensitivity and resistance
O’Sullivan, Julia , Kothari, Charu , Caron, Marie‐Christine, Nonfoux, Louis , Beneyton, Adèle , Coulombe, Yan, Thomas, Mélissa , Atalay, Nurgül, Meng, X. Wei, Milano, Larissa , Jean, Dominique , Boisvert, François‐Michel , Hendzel, Michael J. , Milano, Larissa , Kaufmann, Scott H , Hendzel, Michael J , Masson, Jean Yves , Gagné, Jean‐Philippe , Jin, Zhigang , Kaufmann, Scott H. , Masson, Jean‐Yves , Poirier, Guy G.

Mayo Clinic

Nucleic Acids Research | October 12, 2023 | Volume: 51 | Issue: 20 | Pages: 11056-11079

10.1093/nar/gkad791 | PMID 37823600 Get It

Abstract Zinc finger (ZNF) motifs are some of the most frequently occurring domains in the human genome. It was only recently that ZNF proteins emerged as key regulators of genome integrity in mammalian cells. In this study, we report a new role for the Krüppel-type ZNF-containing protein ZNF432 as a novel poly(ADP-ribose) (PAR) reader that regulates the DNA damage response. We show that ZNF432 is recruited to DNA lesions via DNA- and PAR-dependent mechanisms. Remarkably, ZNF432 stimulates PARP-1 activity in vitro and in cellulo. Knockdown of ZNF432 inhibits phospho-DNA-PKcs and increases RAD51 foci formation following irradiation. Moreover, purified ZNF432 preferentially binds single-stranded DNA and impairs EXO1-mediated DNA resection. Consequently, the loss of ZNF432 in a cellular system leads to resistance to PARP inhibitors while its overexpression results in sensitivity. Taken together, our results support the emerging concept that ZNF-containing proteins can modulate PARylation, which can be embodied by the pivotal role of ZNF432 to finely balance the outcome of PARPi response by regulating homologous recombination.
P‐BB‐6 | A Practical Option for Platelet Shortages: A Warm to Cold Storage Converted Apheresis Platelet Program During the COVID‐19 Pandemic
Hammel, Stephen, Stubbs, James R. , Vrieze, Jop de, Thomas, L., Stensgard, R., Hammel, S., Vrieze, J., Thomas, L., Gandhi, Manish J. , Juskewitch, Justin E.

Mayo Clinic

Transfusion | October 12, 2023 | Volume: 63 | Issue: S5 | Pages: No page available

10.1111/trf.110_17554 Get It

Pulmonary hemodynamics and transplant‐free survival in sarcoidosis‐associated pulmonary hypertension: Results from an international registry
Gayen, S. , Baughman, Robert P. , Nathan, Steven D. , Wells, Athol U. , Alhamad, Esam H. , Culver, Daniel A. , Barney, Joseph B. , Carmoma, Eva M., Cordova, Francis , Huitema, Marloes P. , Scholand, Mary Beth , Ganesh, Sivagini, Birring, Surinder S. , Wort, Stephen J. , Shlobin, Oksana A. , Gayen, Shameek K , Kouranos, Vasileios , Wijsenbeek, Marlies , Price, Laura , Gupta, Rohit

Mayo Clinic

Pulmonary Circulation | October 12, 2023 | Volume: 13 | Issue: 4 | Pages: No page available

10.1002/pul2.12297 | PMID 37840561 Get It

AbstractPulmonary hypertension (PH) is a risk factor for mortality in patients with sarcoidosis. Severe PH in chronic lung disease has previously been defined as mean pulmonary arterial pressure (mPAP) ≥ 35 mmHg or mPAP 25 ≥ mmHg with cardiac index (CI) ≤ 2 L/min/m2. However, there is no clear definition denoting severity of sarcoidosis‐associated PH (SAPH). We aimed to determine pulmonary hemodynamic cut‐off values where transplant‐free survival was worse among patients with SAPH. This was a retrospective cohort analysis of the Registry of SAPH database focusing on pulmonary hemodynamic predictors of transplant‐free survival among patients with precapillary SAPH. Cox regression was performed to determine which pulmonary hemodynamic values predicted death or lung transplantation. Kaplan−Meier survival analysis was performed on statistically significant predictors to determine pulmonary hemodynamic cut‐off values where transplant‐free survival was decreased. Decreased transplant‐free survival occurred among SAPH patients with mPAP ≥ 40 mmHg and SAPH patients with pulmonary vascular resistance (PVR) ≥ 5 Woods units (WU). Transplant‐free survival was not decreased in patients who fulfilled prior criteria of severe PH in chronic lung disease. We identified new cut‐offs with decreased transplant‐free survival in the SAPH population. Neither cut‐off of mPAP ≥ 40 mmHg nor PVR ≥ 5 WU has previously been shown to be associated with decreased transplant‐free survival in SAPH. These values could suggest a new definition of severe SAPH. Our PVR findings are in line with the most recent European Society of Cardiology/European Respiratory Society guideline definition of severe PH in chronic lung disease.